BR9913680A - Composições terapêuticas (ii) - Google Patents

Composições terapêuticas (ii)

Info

Publication number
BR9913680A
BR9913680A BR9913680-5A BR9913680A BR9913680A BR 9913680 A BR9913680 A BR 9913680A BR 9913680 A BR9913680 A BR 9913680A BR 9913680 A BR9913680 A BR 9913680A
Authority
BR
Brazil
Prior art keywords
patient
physiologically acceptable
therapeutic compositions
acceptable ketosis
ketosis
Prior art date
Application number
BR9913680-5A
Other languages
English (en)
Inventor
Richard L Veech
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of BR9913680A publication Critical patent/BR9913680A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

"COMPOSIçõES TERAPêUTICAS (II)" Composições contendo corpos cetona e/ou seus precursores metabólicos são proporcionadas as quais são adequadas para a administração a humanos e animais e que possuem propriedades de, dentre outras, (i) aumentar eficiência cardíaca, particularmente a eficiência no uso da glicose, (ii) para proporcionar fonte de energia, particularmente em estados de diabetes e insulino-resistentes e (iii) tratar distúrbios causados por danos às células cerebrais, particularmente através do retardamento ou prevenção dos danos cerebrais em áreas cerebrais associadas à memória tal como os encontrados em Alzheimer e condições similares. Estas composições podem ser tomadas como auxiliares nutricionais, por exemplo para atletas, ou para o tratamento de condições médicas, particularmente aquelas associadas com fraca eficiência cardíaca, insulino-resistência e danos neuronais. A invenção adicionalmente proporciona métodos de tratamento e novos ésteres e polímeros para a inclusão nas composições da invenção.
BR9913680-5A 1998-09-15 1999-09-15 Composições terapêuticas (ii) BR9913680A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10037198P 1998-09-15 1998-09-15
PCT/US1999/021015 WO2000015216A1 (en) 1998-09-15 1999-09-15 Therapeutic compositions (ii)

Publications (1)

Publication Number Publication Date
BR9913680A true BR9913680A (pt) 2001-06-05

Family

ID=22279402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913680-5A BR9913680A (pt) 1998-09-15 1999-09-15 Composições terapêuticas (ii)

Country Status (18)

Country Link
US (2) US20010014696A1 (pt)
EP (1) EP1123094B1 (pt)
JP (1) JP2002524506A (pt)
KR (1) KR100805490B1 (pt)
CN (1) CN1273129C (pt)
AT (1) ATE359069T1 (pt)
AU (1) AU767238B2 (pt)
BR (1) BR9913680A (pt)
CA (1) CA2339941A1 (pt)
DE (1) DE69935799T2 (pt)
DK (1) DK1123094T3 (pt)
ES (1) ES2283133T3 (pt)
HK (1) HK1035665A1 (pt)
NZ (1) NZ509739A (pt)
PT (1) PT1123094E (pt)
RU (1) RU2242227C2 (pt)
WO (1) WO2000015216A1 (pt)
ZA (1) ZA200101260B (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
DK1292294T3 (da) 2000-05-01 2009-06-22 Accera Inc Anvendelse af mediumkæde-triglycerider til behandling og forebyggelse af Alzheimers sygdom
AU2004245567B2 (en) 2003-06-03 2011-06-23 Oxford University Innovation Limited Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives
EP1661574B1 (en) * 2003-09-01 2017-04-19 Earthus, Inc. Beta-hydroxy short to medium chain fatty acid polymer
US7132221B2 (en) * 2003-09-12 2006-11-07 Headway Technologies, Inc. Method to print photoresist lines with negative sidewalls
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
US7485743B2 (en) 2004-07-20 2009-02-03 Btg International Limited Oligomeric ketone compounds
US20070281892A1 (en) * 2004-09-21 2007-12-06 Martin Keith F Dopaminergic Mimetics
GB0427145D0 (en) * 2004-12-10 2005-01-12 Ketocytonyx Inc Compositions for use in surgery
US20070135376A1 (en) 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
HUE035852T2 (en) 2006-04-03 2018-05-28 Accera Inc Use of ketogen compounds to treat memory decline
WO2008005818A1 (en) * 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
CN104224823A (zh) * 2007-03-30 2014-12-24 有限会社爱泽世 生酮作用促进剂组合物
WO2008128095A1 (en) * 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
CN101293831B (zh) * 2007-04-27 2013-09-18 汕头大学 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途
ES2556535T3 (es) * 2007-07-31 2016-01-18 Accera, Inc. Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
AU2009204370B2 (en) 2008-01-04 2014-12-04 Gvmt Of The Usa, As Represented By The Secretary, Department Of Health & Human Services Ketone bodies and ketone body esters as blood lipid lowering agents
CN102105071A (zh) 2008-07-03 2011-06-22 艾克塞拉公司 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
KR20110115589A (ko) 2009-01-24 2011-10-21 파이토팜 피엘씨 신경영양인자가 매개된 장애의 치료
JP5822845B2 (ja) * 2010-01-08 2015-11-25 アイシス ファーマシューティカルズ， インコーポレーテッド アンジオポエチン様３発現の調節
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
EP2595621A1 (en) 2010-07-20 2013-05-29 Phytopharm PLC Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
CA2922223C (en) 2012-11-05 2021-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services And Human Services Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
PE20151949A1 (es) 2013-03-19 2016-01-05 Univ South Florida Composiciones y metodos para producir cetosis elevada y sostenida
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
JP7514457B2 (ja) * 2016-12-21 2024-07-11 ウニヴェルズィテーツ－キンダースピタル バイダアー バーゼル 片頭痛の予防および治療
MX2019007597A (es) * 2016-12-23 2019-12-19 Univ Leuven Kath 3-hidroxibutirato solo o en combinacion para su uso en el tratamiento de cuidados intensivos.
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
GB2572185A (en) * 2018-03-21 2019-09-25 Chain Biotechnology Ltd Pharmaceutical compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900022854A1 (it) * 2019-12-03 2021-06-03 Dr Schaer S P A Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica
CA3219283A1 (en) 2021-07-17 2023-01-26 Elena GROSS Combination of a ketone body or ketogenic compound with an analgesic or antioxidant
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286842A (en) * 1991-07-01 1994-02-15 Mitsubishi Kasei Corporation Process for producing a biodegradable polymer
JP2885261B2 (ja) * 1993-05-17 1999-04-19 三菱瓦斯化学株式会社 ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
EP2283834B1 (en) * 1997-03-17 2016-07-13 BTG International Limited Therapeutic compositions comprising ketone bodies or their precursors
WO1999034687A1 (en) * 1998-01-07 1999-07-15 Metabolix, Inc. Animal nutrition compositions
EP1098655B1 (en) * 1998-07-22 2004-11-24 Metabolix, Inc. Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers

Also Published As

Publication number Publication date
DE69935799T2 (de) 2007-12-27
NZ509739A (en) 2003-10-31
ES2283133T3 (es) 2007-10-16
DE69935799D1 (de) 2007-05-24
JP2002524506A (ja) 2002-08-06
US20010014696A1 (en) 2001-08-16
RU2242227C2 (ru) 2004-12-20
ATE359069T1 (de) 2007-05-15
EP1123094A1 (en) 2001-08-16
CA2339941A1 (en) 2000-03-23
AU5921299A (en) 2000-04-03
KR100805490B1 (ko) 2008-02-20
US20040171671A1 (en) 2004-09-02
ZA200101260B (en) 2001-08-16
EP1123094B1 (en) 2007-04-11
WO2000015216A1 (en) 2000-03-23
AU767238B2 (en) 2003-11-06
US7351736B2 (en) 2008-04-01
HK1035665A1 (en) 2001-12-07
EP1123094A4 (en) 2001-10-04
PT1123094E (pt) 2007-06-28
DK1123094T3 (da) 2007-08-20
CN1316902A (zh) 2001-10-10
CN1273129C (zh) 2006-09-06
KR20010079830A (ko) 2001-08-22

Similar Documents

Publication Publication Date Title
BR9913680A (pt) Composições terapêuticas (ii)
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
MX9203543A (es) Medicamento.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
RU94045155A (ru) Способы ингибирования болезни альцгеймера
NL300382I1 (nl) Treatment of pompe's disease
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
CA2223403A1 (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds
NO20004311L (no) Farmasøytisk sammensetning av topiramat
ATE262909T1 (de) Intravenöse alendronatformulierungen
SE8704248D0 (sv) Medical use
DE3879873D1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR900015718A (ko) 골관절염 치료제
RU94044454A (ru) Ингибитор аутоимунных заболеваний
SE8500996D0 (sv) Method of treatment
LV11882A (lv) Aminotetralina atvasinajumi sirds un asinsvadu slimibu arstesana
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
Dressler et al. Tic of the respiratory muscles: Report of three cases and review of literature
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
SU944583A1 (ru) Способ реабилитации травматических поражений мышц
UA10301A (uk) Спосіб лікуваhhя раку шлуhку
DK601788D0 (da) Anvendelse af antibiotikaene ll-e19020alfa og ll-e19020beta til behandling af visse fjerkraesygdomme
UA30251A (uk) Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця
RU2000106699A (ru) Способ лечения заболеваний методом настройки биоритмов организма

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO APRESENTA REIVINDICACOES QUE NAO ATENDEM AO REQUISITO DE ATIVIDADE INVENTIVA ( ARTIGO 8O E ARTIGO 13 DA LEI 9279/96 ) E QUE NAO ESTAO SUFICIENTEMENTE DESCRITAS E FUNDAMENTADAS NO RELATORIO DESCRITIVO ( ARTIGOS 24 E 25 DA LEI 9279/96 ).

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.